ROTUOC
ALXN

Regents of the University of California’s Alexion Pharmaceuticals ALXN Stock Holding History

Regents of the University of California’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-39,485
Closed -$3.64M – 98
2013
Q2 		$3.64M Buy
+39,485
New +$3.81M 1.96% 16

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Regents of the University of California's ALXN Position: Q3 2013 in Review

Regents of the University of California sold out of Alexion Pharmaceuticals (ALXN) in Q3 2013, closing a stake of 39,485 shares — an estimated $3.64M sold.

Regents of the University of California first reported a position in ALXN in Q2 2013 and held it in 1 quarter. The position peaked at $3.64M in Q2 2013. 437 funds tracked by Wall St. Rank hold ALXN as of Q3 2013.

  • Regents of the University of California reported no remaining Alexion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Regents of the University of California sold 39,485 Alexion Pharmaceuticals shares in Q3 2013, an estimated $3.64M.
  • Regents of the University of California first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Regents of the University of California's Alexion Pharmaceuticals position peaked at $3.64M in Q2 2013.
  • 437 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2013.

Based on Regents of the University of California's 13F filing for Q3 2013, filed 28 Oct 2013.